Novartis and Ionis Pharmaceuticals Face Setback in Pelacarsen Trial
Carlsbad, California — September 4, 2026 Ionis Pharmaceuticals and partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON...
Ionis Pharmaceuticals
Advertisement
Ionis and AstraZeneca Showcase Cardiovascular Pipeline Progress with New Data at ESC Congress 2026
CARLSBAD, California, August 20, 2026 Ionis Pharmaceuticals, Inc. announced that new clinical data supporting its severe hypertriglyceridemia (sHTG) treatment...
AstraZeneca Reports Wainua Phase III ATTR-CM Trial Results
CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...
Ionis Reaches Phase 3 Enrollment Milestone for Obudanersen
CARLSBAD, Calif., July 6, 2026 Ionis Pharmaceuticals announced the completion of enrollment for the pivotal pediatric cohort of its...
Ionis Wins FDA Approval for TRYNGOLZA in Severe Hypertriglyceridemia
CARLSBAD, Calif., June 24, 2026 Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA®...
Advertisements
Ionis Zilganersen NDA Gets FDA Priority Review
CARLSBAD, California, March 23, 2026 Ionis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted...
WINREVAIR Achieves Phase 2 Success in CpcPH Due to HFpEF
RAHWAY, N.J., Nov. 18, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 2 CADENCE study,...
DAWNZERA Wins CHMP Backing for Preventing Hereditary Angioedema Attacks
Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...
Advertisement
